Description
COMPOSITION:
Each LuciMob capsule contains: 48.06mg Mobocertinib succinate equivalent to Mobocertinib 40mg
INDICATION:
LuciMob is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
DOSAGE AND USE:
The recommended dosage of LuciMob is 160 mg orally once daily until disease progression or unacceptable toxicity.
Capsule should be swallowed whole & not chewed or crushed.
STORAGE:
in a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY:
LUCIUS PHARMACEUTICALS(LAO) CO., LTD
No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING:
Keep medicine out of the reach of Children. Do not administered LuciMob in Pregnancy and Lactation patient treatment.
Reviews
There are no reviews yet.